Provided by Tiger Fintech (Singapore) Pte. Ltd.

Transcontinental Realty Investors

40.55
+0.33000.82%
Post-market: 40.550.00000.00%16:08 EDT
Volume:2.75K
Turnover:109.19K
Market Cap:350.32M
PE:44.17
High:40.55
Open:38.35
Low:38.35
Close:40.22
Loading ...

Transcontinental Realty Inc falls -9.1%

TIPRANKS
·
12 Jun

Transcontinental Realty Down Over 9%, On Pace For Largest Percent Decrease Since September 2023 -- Data Talk

Dow Jones
·
11 Jun

Transcontinental Realty Investors Inc. Reports Acquisition of Common Shares in Income Opportunity Realty Investors Inc

Reuters
·
06 Jun

TCI Finance CFO to Retire

MT Newswires Live
·
16 May

Transcontinental Realty Q1 EPS $0.53 Up From $0.30 YoY, Sales $12.01M Up From $11.90M YoY

Benzinga
·
09 May

BRIEF-Transcontinental Realty Investors Q1 Net Income USD 4.781 Million

Reuters
·
09 May

Press Release: Transcontinental Realty Investors, Inc. Reports Earnings for Quarter Ended March 31, 2025

Dow Jones
·
09 May

BRIEF-Transcontinental Realty Investors Inc says Qtrly EPS $0.53

Reuters
·
09 May

Transcontinental Realty Investors Inc: Qtrly EPS $0.53

THOMSON REUTERS
·
09 May

AMGEN REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS

PR Newswire
·
02 May

Transcontinental Realty Investors Full Year 2024 Earnings: EPS: US$0.68 (vs US$0.69 in FY 2023)

Simply Wall St.
·
22 Mar

Transcontinental Realty Q4 EPS $0.01 Up From $(0.30) YoY, Total Revenue $11.79M Down From $13.45M YoY

Benzinga
·
21 Mar

BRIEF-Transcontinental Realty Investors Q4 Net Income USD 296 Thousand

Reuters
·
21 Mar

Press Release: Transcontinental Realty Investors, Inc. Reports Earnings for Quarter Ended December 31, 2024

Dow Jones
·
21 Mar

BRIEF-Transcontinental Realty Investors Posts Q4 EPS $0.01

Reuters
·
21 Mar

Transcontinental Realty Investors Inc - Q4 Net Income of $0.1 Million or $0.01 per Share

THOMSON REUTERS
·
21 Mar

AMGN's Eczema Drug Meets Goal in Two Late-Stage Studies

Zacks
·
10 Mar

AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

PR Newswire
·
08 Mar

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

PR Newswire
·
07 Mar

Jefferies Remains a Buy on TCI Express Ltd. (TCIEXP)

TIPRANKS
·
09 Feb